Almitas Capital LLC Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Almitas Capital LLC raised its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 4.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,122,597 shares of the company’s stock after acquiring an additional 90,227 shares during the quarter. Amylyx Pharmaceuticals makes up about 2.5% of Almitas Capital LLC’s portfolio, making the stock its 5th biggest position. Almitas Capital LLC owned approximately 2.38% of Amylyx Pharmaceuticals worth $7,514,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of AMLX. Dimensional Fund Advisors LP bought a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at $205,000. Tower Research Capital LLC TRC boosted its position in Amylyx Pharmaceuticals by 377.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 45,987 shares of the company’s stock valued at $174,000 after acquiring an additional 36,347 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at $127,000. Northern Trust Corp boosted its position in Amylyx Pharmaceuticals by 11.8% during the 4th quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock valued at $403,000 after acquiring an additional 11,214 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its position in Amylyx Pharmaceuticals by 16.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 193,931 shares of the company’s stock valued at $733,000 after acquiring an additional 27,502 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AMLX. The Goldman Sachs Group raised Amylyx Pharmaceuticals to a “buy” rating and set a $10.00 target price on the stock in a research report on Thursday, July 10th. Mizuho increased their target price on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the company an “outperform” rating in a research report on Wednesday, May 14th. Jefferies Financial Group started coverage on Amylyx Pharmaceuticals in a report on Tuesday, June 24th. They set a “hold” rating for the company. Guggenheim started coverage on Amylyx Pharmaceuticals in a report on Tuesday, June 24th. They set a “buy” rating and a $17.00 price objective for the company. Finally, Leerink Partnrs upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $12.25.

Amylyx Pharmaceuticals Trading Up 6.4%

Shares of AMLX opened at $9.98 on Wednesday. The firm has a market cap of $889.92 million, a PE ratio of -3.99 and a beta of -0.44. The stock has a fifty day moving average price of $7.93 and a 200-day moving average price of $5.58. Amylyx Pharmaceuticals, Inc. has a 12 month low of $2.08 and a 12 month high of $9.99.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.02). As a group, research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.